Schuler M - Search Results

1

Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.

Meiler J, Guyot M, Hoffarth S, Wesarg E, Höhn Y, Breitenbuecher F, Schuler M. Meiler J, et al. Among authors: schuler m. J Cancer Res Clin Oncol. 2012 Aug;138(8):1385-94. doi: 10.1007/s00432-012-1220-4. Epub 2012 Apr 10. J Cancer Res Clin Oncol. 2012. PMID: 22488173

2

The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases.

Milosevic J, Hoffarth S, Huber C, Schuler M. Milosevic J, et al. Among authors: schuler m. Oncogene. 2003 Oct 9;22(44):6852-6. doi: 10.1038/sj.onc.1206716. Oncogene. 2003. PMID: 14534531

3

Therapeutic targeting of apoptotic pathways in cancer.

Meiler J, Schuler M. Meiler J, et al. Among authors: schuler m. Curr Drug Targets. 2006 Oct;7(10):1361-9. doi: 10.2174/138945006778559175. Curr Drug Targets. 2006. PMID: 17073598 Review.

4

Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.

Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, Schuler M. Wesarg E, et al. Among authors: schuler m. Int J Cancer. 2007 Dec 1;121(11):2387-94. doi: 10.1002/ijc.22977. Int J Cancer. 2007. PMID: 17688235

5

Targeting AKT signaling sensitizes cancer to cellular immunotherapy.

Hähnel PS, Thaler S, Antunes E, Huber C, Theobald M, Schuler M. Hähnel PS, et al. Among authors: schuler m. Cancer Res. 2008 May 15;68(10):3899-906. doi: 10.1158/0008-5472.CAN-07-6286. Cancer Res. 2008. PMID: 18483275

6

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.

Stolz C, Hess G, Hähnel PS, Grabellus F, Hoffarth S, Schmid KW, Schuler M. Stolz C, et al. Among authors: schuler m. Blood. 2008 Oct 15;112(8):3312-21. doi: 10.1182/blood-2007-11-124487. Epub 2008 Aug 8. Blood. 2008. PMID: 18689543 Free article.

7

Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.

Bauer S, Mühlenberg T, Leahy M, Hoiczyk M, Gauler T, Schuler M, Looijenga L. Bauer S, et al. Among authors: schuler m. Eur Urol. 2010 Apr;57(4):679-87. doi: 10.1016/j.eururo.2009.06.014. Epub 2009 Jun 21. Eur Urol. 2010. PMID: 19560254

8

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.

Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S. Mühlenberg T, et al. Among authors: schuler m. Cancer Res. 2009 Sep 1;69(17):6941-50. doi: 10.1158/0008-5472.CAN-08-4004. Epub 2009 Aug 25. Cancer Res. 2009. PMID: 19706776 Free PMC article.

9

The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.

Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J. Sebastian M, et al. Among authors: schuler m. J Thorac Oncol. 2010 Jul;5(7):1060-7. doi: 10.1097/JTO.0b013e3181d95dd4. J Thorac Oncol. 2010. PMID: 20526206 Free article. Clinical Trial.

10

Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer.

Becker S, Markova B, Wiewrodt R, Hoffarth S, Hähnel PS, Pleiner S, Schmidt LH, Breitenbuecher F, Schuler M. Becker S, et al. Among authors: schuler m. J Thorac Oncol. 2011 Dec;6(12):1976-83. doi: 10.1097/JTO.0b013e31822e59dd. J Thorac Oncol. 2011. PMID: 21892104 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,041 results

Search Page